THE ROLE OF OPHTHALMOFERON IN THE TREATMENT OF VIRAL EYE DISEASES IN TYPE 2 DIABETES PATIENTS WITH DIABETIC RETINOPATHY (Literature review)

DOI: https://doi.org/10.29296/25877305-2018-10-07
Download full text PDF
Issue: 
10
Year: 
2018

Vorobyeva I., Cand. Med. Sci. Russian Medical Academy of Continuing Professional Education, Moscow

This paper revealeda high incidence of viral eye diseases (up to 12–15 million per year) in patients of all ages. The clinical picture of the most frequent viral eye diseases (such as epidemic keratoconjunctivitis, pharyngoconjunctival fever, herpetic conjunctivitis) was analysed. The problem of viral eye diseases is so profound, that it has been actively researched not only in Russia, but also abroad. Recent large-scale domestic and international studies in this field (for the period 2017–2018) are reviewed. Viral eye diseases in type 2 diabetes patients with diabetic retinopathy have a longer duration and progress more rapidly to severe forms of keratoconjunctivitis.The disease often results in the vision loss. Combined treatment with the use of pathogenically-oriented antiviral medications can reduce the risk ofdisease progression. This review also analyses data and clinical examples of severe viral eye damage in type 2 diabetes patients, caused by such factors as: low immunity, reduced protein levels, developing polyneuropathy, decreased corneal sensitivity, prolonged wound healing. The interferon-based eye drops(medication Ophtalmoferon®) are the most preferred treatment of viral eye diseases for different patients, including those with diabetes.
Keywords: 
ophthalmology
viral eye diseases
diabetic retinopathy
antiviral treatment
eye drops
Ophthalmoferon®

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Sun Y., Sun Y. LncRNA HOTTIP improves diabetic retinopathy by regulating the p38-MAPK pathway // Eur. Rev. Med. Pharmacol. Sci. – 2018; 22 (10): 2941–8.
  2. Shosha E., Xu Z., Narayanan S. et al. Mechanisms of Diabetes-Induced Endothelial Cell Senescence: Role of Arginase 1 // Int. J. Mol. Sci. – 2018; 19 (4): 1215. DOI: 10.3390/ijms19041215.
  3. Kovalyuk N., Kaiserman I., Mimouni M. et al. Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study // Acta ophthalmologica. – 2017; 95 (8): 686–92. DOI: 10.1111/aos.13416.
  4. Kuo I. More Than Meets the Eye: Adenoviral Conjunctivitis in Healthcare Settings // Infect. Control Hosp. Epidemiol. – 2017; 38 (11): 1358–60 DOI: 10.1017/ice.2017.194.
  5. Agashe R. Clinical and demographic study of microsporidial keratoconjunctivitis in South India: a 3-year study (2013-2015) // Brit. J. Ophthalmol. – 2017; 101 (10): 1436–9. DOI: 10.1136/bjophthalmol-2016-309845.
  6. Altan-Yaycioglu R. Bilateral disciform keratitis of presumed adenoviral etiology // Indian J. Ophthalmol. – 2018; 66 (1): 132. DOI: 10.4103/ijo.IJO_688_17.
  7. Hashimoto S., Gonzalez G., Harada S. et al. Recombinant type Human mastadenovirus D85 associated with epidemic keratoconjunctivitis since 2015 in Japan // J. Med. Virol. – 2018; 90 (5): 881–9. DOI: 10.1002/jmv.25041.
  8. Li J., Lu X., Jiang B. Adenovirus-associated acute conjunctivitis in Beijing, China, 2011–2013 // VMC Infect. Dis. – 2018; 18: 135. DOI: 10.1186/s12879-018-3014-z.
  9. Sundaramurthy R., Dhodapkar R., Kaliaperumal S. et al. Investigational approach to adenoviral conjunctivitis: comparison of three diagnostic tests using a Bayesian latent class model // J. infect. Dev. Ctries. – 2018; 12 (1): 43–51. DOI: 10.3855/jidc.9439
  10. Majchuk D.Ju., Majchuk Ju.F. Oftal'moferon® – 15 let shirokogo primenenija v lechenii i profilaktike infektsionnyh zabolevanij glaz // Infektsionnye bolezni: novosti, mnenija, obuchenie. – 2017; 1: 82–100.
  11. Majchuk Ju.F. Oftal'moferon v lechenii allergicheskih, infektsionno-allergicheskih, toksiko-allergicheskih kon'junktivitov i bolezni suhogo glaza // Ros. oftal'mol. zhurn. – 2011; 3: 78–84.
  12. Majchuk Ju.F. Oftal'moferon. Pervye stabil'nye glaznye kapli interferona dlja lechenija gerpesvirusnyh i adenovirusnyh zabolevanij glaz / M., 2004; 37 s.
  13. Majchuk Ju.F., Jani E.V. Oftal'moferon v lechenii adenovirusnyh zabolevanij glaz // Okulist. – 2006; 5: 18–9.
  14. Markova E.Ju., Pron'ko N.A., Venediktova L.V. Porazhenija glaz pri virusnyh infektsijah u detej // Detskie infektsii. – 2016; 3: 57–62.
  15. Neroev V.V., Majchuk Ju.F. Zabolevanija kon'junktivy. Gl. 8 // Oftal'mologija: natsional'noe rukovodstvo: kratkoe izdanie / M.: GEOTAR-Med, 2014; s. 366–406.
  16. Orlovskaja L.E., Schipanova A.I., Gaponjuk P.Ja. Opyt primenenija glaznyh kapel' Oftal'moferona dlja lechenija adenovirusnyh zabolevanij glaz. Glaukoma: teorii, tendentsii, tehnologii: sbornik nauchnyh statej / M., 2007; s. 456–61.
  17. Prozornaja L.P., Brzheskij V.V. Effektivnost' preparata «Oftal'moferon» v lechenii hronicheskogo blefarokon'junktivita u detej // Vestn. oftal'mol. – 2017; 5: 46–52.
  18. Surov A.V., Korjakov S.V. K voprosu o profilaktike infektsionnyh oslozhnenij glaz posle eksimerlazernyh operatsij // Med. al'manah. – 2015; 5 (36): 99–101.
  19. Chernakova G.M., Klescheva E.A., Semenova T.B. Sindrom «krasnogo glaza» v praktike vrachej raznyh spetsial'nostej // Infektsionnye bolezni. – 2015; 13 (4): 1–5.